Delayed onset muscle soreness : treatment strategies and performance factors.
Karoline Cheung, Patria Hume, Linda Maxwell
https://pubmed.ncbi.nlm.nih.gov/12617692/Actively Recruiting
Led by Istituti Clinici Scientifici Maugeri SpA · Updated on 2025-12-24
64
Participants Needed
1
Research Sites
30 weeks
Total Duration
Researchers are evaluating two types of early rehabilitation for people recovering from a COPD exacerbation, focusing on severe leg muscle weakness, especially in the quadriceps. The study compares a maximal strength training MST program using high loads and few repetitions to a traditional high-intensity endurance training program. The goal is to see which approach is easier to tolerate, especially regarding breathlessness, and which best improves muscle strength, efficiency, and overall exercise tolerance during recovery. Participants are randomly assigned to one of two training groups. The experimental group performs high-intensity resistance training HIRT with 4 sets of 5 repetitions at 90-95% of their maximum leg press strength, combined with low-intensity cycling at 20% of maximum workload. Sessions occur 5 times per week with a 2 days on, 1 day off cycle. The control group performs high-intensity endurance training HIET cycling at 70% of maximum workload for 25 minutes with progression based on symptoms, combined with low-intensity leg press strength training without progression. After 15 sessions, participants are evaluated and continue a combined training program until discharge. During the study, participants undergo assessments including walking tests, muscle strength measurements, ultrasound scans of muscles and diaphragm, quality of life questionnaires, and fatigue scales at enrollment, after 15 sessions, and at discharge. Researchers monitor heart rate, oxygen levels, symptoms, and side effects such as muscle soreness. The main outcome is reduction in breathlessness during daily activities. Secondary outcomes include functional capacity, fatigue, muscle strength, disease impact, walking efficiency, and satisfaction with training. The trial lasts up to about three weeks post-randomization, providing detailed monitoring throughout rehabilitation.
CONDITIONS
High-intensity Resistance Training in Post-exacerbation COPD
M
Mara Paneroni, PhD, MSc
T
Tiziana Bachetti, Pharm
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Istituti Clinici Scientifici Maugeri SpA
Lead Sponsor
Universita di Verona
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 weeks
Participants undergo a rehabilitation program consisting of either high-intensity resistance training combined with low-intensity cycling or high-intensity endurance training combined with low-intensity resistance training. Training sessions occur 5 times per week over approximately 3 weeks, focusing on improving muscle strength, endurance, and reducing dyspnoea after hospital discharge for COPD exacerbation.
5 visits per week for up to 3 weeks
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Karoline Cheung, Patria Hume, Linda Maxwell
https://pubmed.ncbi.nlm.nih.gov/12617692/Yuhao Jia, Qunxia Zhang
https://pubmed.ncbi.nlm.nih.gov/35065813/V S Probst, T Troosters, F Pitta...
https://pubmed.ncbi.nlm.nih.gov/16540501/Jadwiga A Wedzicha, Marc Miravitlles, John R Hurst...
https://pubmed.ncbi.nlm.nih.gov/28298398/Raolat M Abdulai, Tina Jellesmark Jensen, Naimish R Patel...
https://pubmed.ncbi.nlm.nih.gov/29064260/G Vidotto, M Carone, P W Jones...
https://pubmed.ncbi.nlm.nih.gov/17612984/Nia Luxton, Jennifer A Alison, Judy Wu...
https://pubmed.ncbi.nlm.nih.gov/18811884/M R Miller, J Hankinson, V Brusasco...
https://pubmed.ncbi.nlm.nih.gov/16055882/Geoff Norman
https://pubmed.ncbi.nlm.nih.gov/20146096/Michele Vitacca, Alberto Malovini, Mara Paneroni...
https://pubmed.ncbi.nlm.nih.gov/38296674/Istituti Clinici Scientifici Maugeri SpA
Lead Sponsor
Universita di Verona
Collaborating Sponsor